Umaima Ahmad is CEO and co-founder of 52North, a multi-award-winning med-tech company focused on reinventing the healthcare journey, starting by transforming cancer care with its Neutrocheck® solution. In 2023, 52North became the first ever venture investment of Macmillan Cancer Support, and won MedTech Company of the Year at the Cambridge Independent Science and Technology Awards. In 2022, Umaima was recognised on Management Today’s 35 under 35 Women in Business. She is also a Non-Executive Director at Health Tech Enterprise and the Pharmaceutical Licensing Group, and Editor of the Business Development and Licensing Journal. A former pharmaceutical asset transactor and banking lawyer, Umaima is a graduate of King’s College London, the University of Strasbourg and BPP Law School and holds an MPhil in Bioscience Enterprise from the University of Cambridge.